- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06467344
ABCA4 관련 망막병증에서 ACDN-01을 평가하기 위한 연구(STELLAR)
ACDN-01-001: ABCA4 관련 망막병증 참가자의 망막하 ACDN-01의 안전성, 내약성 및 예비 효능을 평가하기 위한 공개 라벨, 단일 상승 용량 연구
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
연구 개요
상세 설명
This is an open-label, single ascending dose study of ACDN-01 in adult participants with ABCA4-related retinopathy. The study is designed to evaluate the safety, tolerability, and evidence of biological effect of SAD levels (low, medium, and high) of ACDN-01 when delivered subretinally.
Participants will be followed on study for 2 years for the primary safety and preliminary efficacy endpoints, after which they will continue in the study in a 3-year long-term follow-up period, for a total study duration of 5 years.
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
California
-
San Francisco, California, 미국, 94158
- University of San Francisco
-
-
Florida
-
Gainesville, Florida, 미국, 32607
- Vitreo Retinal Associates
-
Miami, Florida, 미국, 33136
- Bascom Palmer Eye Institute
-
-
Maryland
-
Baltimore, Maryland, 미국, 21218
- Wilmer Eye Institute at John Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts Eye and Ear
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48105
- University of Michigan Kellogg Eye Center
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45245
- Cincinnati Eye Institute
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- Casey Eye Institute OHSU
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- Children's Hospital of Philadelphia
-
-
Texas
-
Dallas, Texas, 미국, 75382
- Retina Foundation of the Southwest
-
Houston, Texas, 미국, 77401
- Retina Consultants of Texas
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Presence of mutations in the ABCA4 gene
- ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)
- Area of atrophy located in the macula of the study eye
- BCVA of 20/50 (0.4 logMAR) or worse
Key Exclusion Criteria:
- The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy
- Retinal disease other than ABCA4-related retinopathy
- Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Low dose of ACDN-01
One time low dose of ACDN-01. |
ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection. |
|
실험적: Mid-dose of ACDN-01
One time mid-dose of ACDN-01. |
ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection. |
|
실험적: High dose of ACDN-01
One time high dose of ACDN-01. |
ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety and tolerability of ACDN-01 as measured by the number and severity of adverse events and serious adverse events.
기간: 12 months
|
To evaluate the safety and tolerability of a single dose of ACDN-01 when administered to participants with ABCA4-related retinopathy. |
12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum tolerated dose for subsequent clinical evaluation will be determined by review of all available safety and tolerability data.
기간: 12 months
|
To determine maximum tolerated dose (MTD) for subsequent clinical evaluation. |
12 months
|
|
To evaluate for evidence of preliminary efficacy based on fundus autofluorescence (FAF).
기간: 24 months
|
To evaluate for evidence of preliminary efficacy based on change from baseline in the study eye in the area of macular atrophy in mm2 as measured on FAF over 24 months. |
24 months
|
|
To evaluate for evidence of preliminary efficacy based on optical coherence tomography (OCT).
기간: 24 months
|
To evaluate for evidence of preliminary efficacy based on change from baseline in the study eye in change in thickness in retinal layers as measured on OCT, over 24 months. |
24 months
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on best corrected visual acuity.
기간: 24 months
|
Best Corrected Visual Acuity is measured by number of ETDRS letters read in each eye compared to baseline. |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on patient reported outcome measures.
기간: 24 months
|
Patient-reported outcome measures will be measured by overall and subscale scores on the Michigan Retinal -Degeneration Questionnaire (MRDQ). |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on contrast sensitivity.
기간: 24 months
|
Contrast sensitivity is measured using qCSF tests and will measure number of letters read and change in AUC (area under curve). |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on contrast sensitivity.
기간: 24 months
|
Contrast sensitivity is measured using Pelli-Robson tests and will measure number of letters read and change in AUC (area under curve). |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on microperimetry.
기간: 24 months
|
Retinal sensitivity will be measured by change in the location of detectable points. |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on microperimetry.
기간: 24 months
|
Retinal sensitivity will be measured by change in the intensity (dB) of detectable points. |
24 months
|
|
To assess for evidence of preliminary efficacy of ACDN-01 based on microperimetry.
기간: 24 months
|
Retinal sensitivity will be measured by change in the number of detectable points. |
24 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Murray Abramson, MD, PhD, Ascidian Therapeutics
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- ACDN-01-001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .